Centre Hospitalier Universitaire de Nīmes   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Nimes France (1958)

Organization Overview

First Clinical Trial
2005
NCT03867071
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier Universitaire de Nîmes | Centre Hospitalier Universitaire de Nîmes | Centre Hospitalier Universitaire de Nīmes | CHU Nimes, Nimes University, France | Geoffrey.avis@chu-nimes.fr

Active Ingredients

Drugs in Phase 4 Trials (23)

acetaminophen (tylenol) (1 trial)

acetylsalicylic acid (aspirin) (2 trials)

amikacin (Amikin) (2 trials)

coagulation factor viia (recombinant) (NovoSevenRT) (1 trial)

cyclosporine (sandimmune) (1 trial)

desflurane (suprane) (1 trial)

echinocandins (1 trial)

estradiol (progynon depot) (1 trial)

gentamicin (garamycin) (1 trial)

ketoprofen (orudis) (1 trial)

morphine (2 trials)

nefopam (Acupan) (2 trials)

nitrous oxide (2 trials)

oxycodone (oxycontin) (3 trials)

oxygen (1 trial)

rasagiline (azilect) (1 trial)

remifentanil (ultiva) (1 trial)

risedronate (actonel) (1 trial)

ropivacaine (naropin) (5 trials)

sodium chloride (5 trials)

tramadol (Ultram) (2 trials)

vitamin d3 (3 trials)

xenon xe-133 (2 trials)

Drugs in Phase 3 Trials (6)

buprenorphine (1 trial)

clopidogrel (plavix) (1 trial)

esmolol (brevibloc) (1 trial)

ketamine (ketalar) (1 trial)

levocarnitine (carnitor) (2 trials)

sodium bicarbonate (1 trial)

Drugs in Phase 2 Trials (10)

aldesleukin (Proleukin) (2 trials)

anti-staphylococcus bacteriophage therapy (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

cranberry (1 trial)

durvalumab (imfinzi) (1 trial)

etoposide (vepesid) (1 trial)

gemcitabine (gemzar) (1 trial)

glucose (1 trial)

riluzole (rilutek) (1 trial)

Drugs in Phase 1 Trials (2)

hydrocortisone (solu-cortef) (1 trial)

lidocaine (xylocaine) (1 trial)

Drugs in Other Trials (18)

ceftobiprole (1 trial)

codeine (Phenergan) (1 trial)

dexmedetomidine (precedex) (1 trial)

emtricitabine (emtriva) (1 trial)

erythropoetin beta (1 trial)

florbetaben F-18 (neuraceq) (1 trial)

human choriogonadotropin alfa (hCG) (1 trial)

landiolol (1 trial)

leukocytes (1 trial)

methyl aminolevulinate (metvixia) (1 trial)

platelet-rich plasma (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

silicone (1 trial)

spirulina (1 trial)

sufentanil (1 trial)

tadalafil (cialis) (1 trial)

tamsulosin (flomax) (1 trial)

tenofovir (viread) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 2)

Bacteriuria (Phase 2)

Brain Death (Phase 4)

Bursitis (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Colic (Phase 4)

Communicable Diseases (Phase 2)

Cross Infection (Phase 2)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Foot (Phase 2)

Emergencies (Phase 4)

Foot Ulcer (Phase 2)

Hemorrhage (Phase 4)

Infections (Phase 2)

Kidney Diseases (Phase 3)

Medulloblastoma (Phase 2)

Motor Neuron Disease (Phase 2)

Multiple Sclerosis (Phase 3)

Parkinson Disease (Phase 4)

Peritonitis (Phase 4)

Postpartum Hemorrhage (Phase 4)

Renal Colic (Phase 4)

Renal Insufficiency (Phase 3)

Respiratory Insufficiency (Phase 4)

Sclerosis (Phase 3)

Sepsis (Phase 4)

Shock (Phase 4)

Shock, Septic (Phase 4)

Staphylococcal Infections (Phase 2)

Suicidal Ideation (Phase 3)

Tachycardia (Phase 4)

Tendon Injuries (Phase 4)

Toxemia (Phase 4)

Wounds and Injuries (Phase 3)

Wounds, Nonpenetrating (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 51
  • # of Trial APIs: 59